398 results on '"Bazin R"'
Search Results
102. Rôle du tissu adipeux brun dans le développement de l'obésité génétique du rat Zucker obèse (fa/fa)
- Author
-
BAZIN, R., primary, ETEVE, Dominique, additional, DUPUY, Francine, additional, and LAVAU, Marcelle, additional
- Published
- 1985
- Full Text
- View/download PDF
103. Inguinal fat pad weight plotted versus body weight as a method of genotype identification in 16-day-old Zucker rats
- Author
-
Lavau, M, primary and Bazin, R, additional
- Published
- 1982
- Full Text
- View/download PDF
104. Development of hepatic and adipose tissue lipogenic enzymes and insulinemia during suckling and weaning on to a high-fat diet in Zucker rats
- Author
-
Bazin, R, primary and Lavau, M, additional
- Published
- 1982
- Full Text
- View/download PDF
105. Quantitative Autoradiographic Localization of Neurotensin Binding Sites in Lean and Obese Zucker Rats
- Author
-
Rostène, W., primary, Bazin, R., additional, Morgat, J., additional, Dussaillant, M., additional, and Broer, Y., additional
- Published
- 1985
- Full Text
- View/download PDF
106. Protective effect of the membrane skeleton on the immunologic reactivity of the human red cell Rho(D) antigen.
- Author
-
Paradis, G, primary, Bazin, R, additional, and Lemieux, R, additional
- Published
- 1986
- Full Text
- View/download PDF
107. Role of the macrophage-derived hybridoma growth factor in the in vitro and in vivo proliferation of newly formed B cell hybridomas.
- Author
-
Bazin, R, primary and Lemieux, R, additional
- Published
- 1987
- Full Text
- View/download PDF
108. Quantitative Autoradiographic Localization of Neurotensin Binding Sites in Lean and Obese Zucker Rats
- Author
-
Monique Dussaillant, William Rostène, Jean-Louis Morgat, Y. Broer, and Bazin R
- Subjects
Brain Chemistry ,medicine.medical_specialty ,Endocrinology, Diabetes and Metabolism ,Biochemistry (medical) ,Clinical Biochemistry ,General Medicine ,Biochemistry ,Rats ,Rats, Zucker ,Receptors, Neurotransmitter ,chemistry.chemical_compound ,Endocrinology ,chemistry ,Internal medicine ,medicine ,Animals ,Autoradiography ,Receptors, Neurotensin ,Zucker Rats ,Obesity ,Binding site ,Neurotensin - Published
- 1985
109. Impact of intravenous immunoglobulin on the dopaminergic system and immune response in the acute MPTP mouse model of Parkinson’s disease
- Author
-
St-Amour Isabelle, Bousquet Mélanie, Paré Isabelle, Drouin-Ouellet Janelle, Cicchetti Francesca, Bazin Renée, and Calon Frédéric
- Subjects
Intravenous immunoglobulin ,Parkinson’s disease ,Immunity ,Neurodegeneration ,MPTP ,Dopamine ,Neurology. Diseases of the nervous system ,RC346-429 - Abstract
Abstract Intravenous immunoglobulin (IVIg) is a blood-derived product, used for the treatment of immunodeficiency and autoimmune diseases. Since a range of immunotherapies have recently been proposed as a therapeutic strategy for Parkinson’s disease (PD), we investigated the effects of an IVIg treatment in a neurotoxin-induced animal model of PD. Mice received four injections of MPTP (15 mg/kg) at 2-hour intervals followed by a 14-day IVIg treatment, which induced key immune-related changes such as increased regulatory T-cell population and decreased CD4+/CD8+ ratio. The MPTP treatment induced significant 80% and 84% decreases of striatal dopamine concentrations (P P P
- Published
- 2012
- Full Text
- View/download PDF
110. Quantitative Autoradiographic Localization of Neurotensin Binding Sites in Lean and Obese Zucker Rats.
- Author
-
Rost�ne, W. H., Bazin, R., Morgat, J. L., Dussaillant, M., and Broer, Y.
- Published
- 1985
- Full Text
- View/download PDF
111. Molecular Basis for the False Positive Reactions in HIV-1/2 Enzyme Immunoassays.
- Author
-
Bazin, R., Aubin, E., Roberge, C., and Lemieux, R.
- Subjects
- *
BLOOD testing , *DIRECTED blood donations , *IMMUNOGLOBULINS , *ENZYME-linked immunosorbent assay - Abstract
Background: Screening of blood donations for the presence of antibodies specific to viruses such as HIV is very important for the safety of blood transfusion. The screening is done using enzyme immunoassays (EIAs) and although these tests have a very high specificity (around 99.9%), false positive reactions occur which result in the permanent deferral of uninfected donors. This study was undertaken to better understand the molecular basis of false positive reactions in the HIV-1/2 EIA currently used in our institution. Methods: We used different immunoassays to compare serum from donors with false-positive HIV-1/2 EIA reactivity (RR donors) to serum from HIV seronegative or seropositive individuals. Results: Our results show that the Ig isotype (G, M, A) concentrations in the serum of individuals with a false positive EIA reactivity (RR individuals) are in the normal range. Also, serum from RR individuals does not exhibit a higher degree of polyreactivity compared to serum from HIV seronegative individuals. Our results also show that IgG1 are mostly responsible for the false positive reactivity in HIV-1/2 EIA, although IgG2 were found to be prevalent in a few cases. Finally, no binding could be detected in EIA done in absence of the HIV-1/2 peptides. Conclusions: Our results indicate that most RR individuals have HIV-1/2 cross-reactive IgG1 antibodies in their serum, which are responsible for the false positive reaction in HIV-1/2 EIA. The nature of the stimulus that elicited the production of such cross-reactive antibodies remains unknown. [ABSTRACT FROM AUTHOR]
- Published
- 2001
112. Use of hu-IgG-SCID mice to evaluate the in vivo stability of human monoclonal IgG antibodies
- Author
-
Bazin, R., Boucher, G., Monier, G., and Chevrier, M.-C.
- Published
- 1994
- Full Text
- View/download PDF
113. The use of predictive modelling to determine the likelihood of donor return during the COVID-19 pandemic.
- Author
-
Gammon RR, Hindawi S, Al-Riyami AZ, Ang AL, Bazin R, Bloch EM, Counts K, de Angelis V, Goel R, Grubovic Rastvorceva RM, Pati I, Lee CK, La Raja M, Mengoli C, Oreh A, Patidar GK, Rahimi-Levene N, Ravula U, Rexer K, So-Osman C, Thachil J, Nevessignsky MT, and Vermeulen M
- Abstract
Artificial intelligence (AI) uses sophisticated algorithms to "learn" from large volumes of data. This could be used to optimise recruitment of blood donors through predictive modelling of future blood supply, based on previous donation and transfusion demand. We sought to assess utilisation of predictive modelling and AI blood establishments (BE) and conducted predictive modelling to illustrate its use. A BE survey of data modelling and AI was disseminated to the International Society of Blood transfusion members. Additional anonymzed data were obtained from Italy, Singapore and the United States (US) to build predictive models for each region, using January 2018 through August 2019 data to determine likelihood of donation within a prescribed number of months. Donations were from March 2020 to June 2021. Ninety ISBT members responded to the survey. Predictive modelling was used by 33 (36.7%) respondents and 12 (13.3%) reported AI use. Forty-four (48.9%) indicated their institutions do not utilise predictive modelling nor AI to predict transfusion demand or optimise donor recruitment. In the predictive modelling case study involving three sites, the most important variable for predicting donor return was number of previous donations for Italy and the US, and donation frequency for Singapore. Donation rates declined in each region during COVID-19. Throughout the observation period the predictive model was able to consistently identify those individuals who were most likely to return to donate blood. The majority of BE do not use predictive modelling and AI. The effectiveness of predictive model in determining likelihood of donor return was validated; implementation of this method could prove useful for BE operations., (© 2024 British Blood Transfusion Society.)
- Published
- 2024
- Full Text
- View/download PDF
114. Incidence of SARS-CoV-2 during the Omicron wave: Results of a longitudinal serosurvey in Québec, Canada.
- Author
-
Lewin A, Germain M, Bazin R, Grégoire Y, De Serres G, and Renaud C
- Abstract
Objectives: Conventional serological approaches lack sensitivity for the detection of recent SARS-CoV-2 infections in vaccinated individuals, as these individuals exhibit a blunted anti-nucleocapsid (N) response. This limitation was recently addressed by the development of a "ratio-based approach", which compares longitudinally collected specimens. Here, we used this approach to estimate the incidence of SARS-CoV-2 infection and reinfection in Québec (Canada) during the Omicron wave., Methods: Consenting plasma donors were included if they donated plasma before December 15, 2021 and during six consecutive periods of ~ 3 months between December 15, 2021 and July 7, 2023 (study period). Anti-N levels were measured with an enzyme-linked immunosorbent assay, and seroconversion was characterized by a ratio of ≥ 1.5 between the optical density of two consecutive samples., Results: Among the 254 donors, the adjusted proportion of donors (95% confidence interval [CI]) with a new infection ranged between 18.1% (13.2‒23.0) and 24.2% (18.8‒29.7) over Periods 1-5 and fell to 7.9% (4.9‒11.0) during Period 6. During the study period, the proportion of newly infected donors decreased among those aged < 60 (Period 1 = 31.6%, Period 5 = 4.4%), but increased among those aged ≥ 70 (Period 1 = 0.3%, Period 6 = 10.3%). Throughout the study period, 72 (28.3%) reinfections occurred, including two seroconversion events in a single donor. Overall, 87.4% (95% CI = 82.7‒91.2) were infected by SARS-CoV-2 at least once during the study period., Conclusion: The vast majority of the Québec population may have been infected during the Omicron wave. This longitudinal survey demonstrates the usefulness of the "ratio-based approach" for identifying both new infections and reinfections in a vaccinated population., (© 2024. The Author(s) under exclusive license to The Canadian Public Health Association.)
- Published
- 2024
- Full Text
- View/download PDF
115. SARS-CoV-2 immunoassays in a predominantly vaccinated population: Performances and qualitative agreements obtained with two analytical approaches and four immunoassays.
- Author
-
Renaud C, Lewin A, Gregoire Y, Simard N, Vallières É, Paquette M, Drews SJ, O'Brien SF, Di Germanio C, Busch MP, Germain M, and Bazin R
- Subjects
- Humans, Immunoassay methods, Female, Male, Adult, COVID-19 Serological Testing methods, Middle Aged, Immunoglobulin G blood, Seroepidemiologic Studies, Vaccination, Blood Donors, SARS-CoV-2 immunology, COVID-19 prevention & control, COVID-19 blood, COVID-19 immunology, COVID-19 epidemiology, Antibodies, Viral blood, COVID-19 Vaccines immunology
- Abstract
Background and Objectives: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) serosurveys are typically analysed by applying a fixed threshold for seropositivity ('conventional approach'). However, this approach underestimates the seroprevalence of anti-nucleocapsid (N) in vaccinated individuals-who often exhibit a difficult-to-detect anti-N response. This limitation is compounded by delays between the onset of infection and sample collection. To address this issue, we compared the performance of four immunoassays using a new analytical approach ('ratio-based approach'), which determines seropositivity based on an increase in anti-N levels., Materials and Methods: Two groups of plasma donors and four immunoassays (Elecsys total anti-N, VITROS total anti-N, Architect anti-N Immunoglobulin G (IgG) and in-house total anti-N) were evaluated. First-group donors (N = 145) had one positive SARS-CoV-2 polymerase chain reaction (PCR) test result and had made two plasma donations, including one before and one after the PCR test (median = 27 days post-PCR). Second-group donors (N = 100) had made two plasma donations early in the Omicron wave., Results: Among first-group donors (97.9% vaccinated), sensitivity estimates ranged from 60.0% to 89.0% with the conventional approach, compared with 94.5% to 98.6% with the ratio-based approach. Among second-group donors, Fleiss's κ ranged from 0.56 to 0.83 with the conventional approach, compared with 0.90 to 1.00 with the ratio-based approach., Conclusion: With the conventional approach, the sensitivity of four immunoassays-measured in a predominantly vaccinated population based on samples collected ~1 month after a positive test result-fell below regulatory agencies requirement of ≥95%. The ratio-based approach significantly improved the sensitivities and qualitative agreement among immunoassays, to the point where all would meet this requirement., (© 2024 International Society of Blood Transfusion.)
- Published
- 2024
- Full Text
- View/download PDF
116. Quality of life and cost-effectiveness of convalescent plasma compared to standard care for hospitalized COVID-19 patients in the CONCOR-1 trial.
- Author
-
Tse P, Yan J, Liu Y, Jamula E, Heddle N, Bazin R, Robitaille N, Cook R, Turgeon A, Fergusson D, Glesby M, Loftsgard KC, Cushing M, Chassé M, Daneman N, Finzi A, Sachais B, Bégin P, Callum J, Arnold DM, and Xie F
- Subjects
- Adult, Humans, Quality of Life, Bisoprolol, Cost-Benefit Analysis, COVID-19 Serotherapy, Canada epidemiology, COVID-19 therapy
- Abstract
Background: The CONvalescent Plasma for Hospitalized Adults With COVID-19 Respiratory Illness (CONCOR-1) trial was a multicenter randomized controlled trial assessing convalescent plasma in hospitalized COVID-19 patients. This study evaluates the cost-effectiveness of convalescent plasma and its impact on quality-of-life to provide insight into its potential as an alternative treatment in resource-constrained settings., Methods: Individual patient data on health outcomes and resource utilization from the CONCOR-1 trial were used to conduct the analysis from the Canadian public payer's perspective with a time horizon of 30 days post-randomization. Baseline and 30-day EQ-5D-5L were measured to calculate quality-adjusted survival. All costs are presented in 2021 Canadian dollars. The base case assessed the EQ-5D-5L scores of hospitalized inpatients reporting at both timepoints, and a utility score of 0 was assigned for patients who died within 30 days. Costs for all patients enrolled were used. The sensitivity analysis utilizes EQ-5D-5L scores from the same population but only uses costs from this population., Results: 940 patients were randomized: 627 received CCP and 313 received standard care. The total costs were $28,716 (standard deviation, $25,380) and $24,258 ($22,939) for the convalescent plasma and standard care arms respectively. EQ-5D-5L scores were 0.61 in both arms (p = .85) at baseline. At 30 days, EQ-5D-5L scores were 0.63 and 0.64 for patients in the convalescent plasma and standard care arms, respectively (p = .46). The incremental cost was $4458 and the incremental quality-adjusted life day was -0.078., Discussion: Convalescent plasma was less effective and more costly than standard care in treating hospitalized COVID-19., (© 2024 The Authors. Transfusion published by Wiley Periodicals LLC on behalf of AABB.)
- Published
- 2024
- Full Text
- View/download PDF
117. Bioluminescence imaging reveals enhanced SARS-CoV-2 clearance in mice with combinatorial regimens.
- Author
-
Ullah I, Escudie F, Scandale I, Gilani Z, Gendron-Lepage G, Gaudette F, Mowbray C, Fraisse L, Bazin R, Finzi A, Mothes W, Kumar P, Chatelain E, and Uchil PD
- Abstract
Direct acting antivirals (DAAs) represent critical tools for combating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs) that have escaped vaccine-elicited spike-based immunity and future coronaviruses with pandemic potential. Here, we used bioluminescence imaging to evaluate therapeutic efficacy of DAAs that target SARS-CoV-2 RNA-dependent RNA polymerase (favipiravir, molnupiravir) or main protease (nirmatrelvir) against Delta or Omicron VOCs in K18-hACE2 mice. Nirmatrelvir displayed the best efficacy followed by molnupiravir and favipiravir in suppressing viral loads in the lung. Unlike neutralizing antibody treatment, DAA monotherapy regimens did not eradicate SARS-CoV-2 in mice, but combining molnupiravir with nirmatrelvir exhibited superior additive efficacy and led to virus clearance. Furthermore, combining molnupiravir with caspase-1/4 inhibitor mitigated inflammation and lung pathology whereas combining molnupiravir with COVID-19 convalescent plasma demonstrated synergy, rapid virus clearance, and 100% survival. Thus, our study provides insights into in vivo treatment efficacies of DAAs and other effective combinations to bolster COVID-19 therapeutic arsenal., Competing Interests: The authors declare no competing interests., (© 2024 The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
118. Risk factors for T-cell lymphopenia in frequent platelet donors: The BEST collaborative study.
- Author
-
Kaufman RM, Marks DC, Flamand Y, Acker JP, Brown BL, Olafson C, Marschner S, Pandey S, Papari M, Petraszko T, Serrano K, Ward D, and Bazin R
- Subjects
- Humans, Plateletpheresis methods, Blood Donors, Leukocytes, Blood Platelets, Lymphopenia etiology
- Abstract
Background: Severe T-cell lymphopenia of uncertain clinical significance has been observed in frequent apheresis platelet donors. Two commonly used plateletpheresis instruments are the Trima Accel, which uses a leukoreduction system (LRS) chamber to trap leukocytes and the Fenwal Amicus, which does not use an LRS chamber., Study Design and Methods: We performed an international, multicenter, observational study comparing T-cell populations in frequent platelet donors collected exclusively using the Trima instrument (n = 131) or the Amicus instrument (n = 77). Age- and sex-matched whole blood donors (n = 126) served as controls., Results: CD4
+ T-cell counts <200 cells/μL were found in 9.9% of frequent Trima (LRS+) platelet donors, 4.4% of frequent Amicus (LRS-) platelet donors, and 0 whole blood donors (p < .0001). CD4+ T-cell counts <200 cells/μL were only seen in platelet donors with ≥200 lifetime donations. In multivariable analysis, age, lifetime donations, and instrument (Trima vs. Amicus) were independent risk factors for lymphopenia. In 40 Trima platelet donors, a plasma rinseback procedure was routinely performed following platelet collections. No Trima platelet donors receiving plasma rinseback had a CD4+ T-cell count <200 cells/μL versus 13/91 Trima platelet donors not receiving plasma rinseback (p = .01)., Discussion: Recurrent bulk lymphocyte removal appears to contribute to the development of T-cell lymphopenia in frequent, long-term platelet donors. Lymphopenia is more common when an LRS chamber is used during platelet collection but can occur without an LRS chamber. Blood centers using LRS chambers can mitigate donor lymphopenia by performing plasma rinseback., (© 2023 AABB.)- Published
- 2023
- Full Text
- View/download PDF
119. Humoral Responses Elicited after a Fifth Dose of SARS-CoV-2 mRNA Bivalent Vaccine.
- Author
-
Tauzin A, Beaudoin-Bussières G, Benlarbi M, Nayrac M, Bo Y, Gendron-Lepage G, Medjahed H, Perreault J, Gokool L, Arlotto P, Morrisseau C, Tremblay C, Kaufmann DE, Martel-Laferrière V, Levade I, Côté M, Bazin R, and Finzi A
- Subjects
- Humans, Antibodies, Vaccines, Combined, RNA, Messenger genetics, SARS-CoV-2 genetics, COVID-19 prevention & control
- Abstract
While an important part of the world's population is vaccinated against SARS-CoV-2, new variants continue to emerge. We observe that even after a fifth dose of the mRNA bivalent vaccine, most vaccinated individuals have antibodies that poorly neutralize several Omicron subvariants, including BQ.1.1, XBB, XBB.1.5, FD.1.1, and CH.1.1. However, Fc-effector functions remain strong and stable over time against new variants, which may partially explain why vaccines continue to be effective. We also observe that donors who have been recently infected have stronger antibody functional activities, including neutralization and Fc-effector functions, supporting the observations that hybrid immunity leads to better humoral responses.
- Published
- 2023
- Full Text
- View/download PDF
120. Combinatorial Regimens Augment Drug Monotherapy for SARS-CoV-2 Clearance in Mice.
- Author
-
Ullah I, Escudie F, Scandale I, Gilani Z, Gendron-Lepage G, Gaudette F, Mowbray C, Fraisse L, Bazin R, Finzi A, Mothes W, Kumar P, Chatelain E, and Uchil PD
- Abstract
Direct acting antivirals (DAAs) represent critical tools for combating SARS-CoV-2 variants of concern (VOCs) that evolve to escape spike-based immunity and future coronaviruses with pandemic potential. Here, we used bioluminescence imaging to evaluate therapeutic efficacy of DAAs that target SARS-CoV-2 RNA-dependent RNA polymerase (favipiravir, molnupiravir) or Main protease (nirmatrelvir) against Delta or Omicron VOCs in K18-hACE2 mice. Nirmatrelvir displayed the best efficacy followed by molnupiravir and favipiravir in suppressing viral loads in the lung. Unlike neutralizing antibody treatment, DAA monotherapy did not eliminate SARS-CoV-2 in mice. However, targeting two viral enzymes by combining molnupiravir with nirmatrelvir resulted in superior efficacy and virus clearance. Furthermore, combining molnupiravir with Caspase-1/4 inhibitor mitigated inflammation and lung pathology whereas combining molnupiravir with COVID-19 convalescent plasma yielded rapid virus clearance and 100% survival. Thus, our study provides insights into treatment efficacies of DAAs and other effective combinations to bolster COVID-19 therapeutic arsenal.
- Published
- 2023
- Full Text
- View/download PDF
121. Evaluation of anti-nucleocapsid level variation to assess SARS-CoV-2 seroprevalence in a vaccinated population.
- Author
-
Bazin R, Rochette S, Perreault J, Fournier MJ, Grégoire Y, Boivin A, Lewin A, Germain M, and Renaud C
- Subjects
- Humans, Seroepidemiologic Studies, Enzyme-Linked Immunosorbent Assay, Pandemics, Antibodies, Viral, SARS-CoV-2, COVID-19 diagnosis, COVID-19 epidemiology, COVID-19 prevention & control
- Abstract
Background: Serosurveys have been key to public health decision-making since the beginning of the SARS-CoV-2 pandemic. However, several studies have uncovered that vaccination blunts the anti-nucleocapsid (N) response to a subsequent infection, which hinders the ability of serologic assays (including commercial ones) to detect recent infections. We therefore developed a new analytical approach to increase the sensitivity of detection of infection in vaccinated individuals., Methods: Two samples were obtained from 248 SARS-CoV-2-positive (PCR-confirmed), vaccinated donors: one before the infection (reference sample) and one after (test sample). All samples were tested using an in-house, anti-N enzyme-linked immunosorbent assay (ELISA) which had a sensitivity of 98.1% before the mass vaccination campaign. Instead of applying a seropositivity threshold based on a single absorbance value (i.e. conventional approach), seropositivity was determined based on the ratio between the anti-N absorbance of the test and reference samples., Results: The sensitivity of the new approach to detect infection in vaccinated individuals was 95.2% using a cut-off of 1.5 for the anti-N ratio, whereas that of the conventional approach was 63.3%., Conclusion: The new analytical approach described herein captured a significantly greater proportion of vaccinated individuals with a known history of SARS-CoV-2 infection than the conventional approach used in most serosurveys.
- Published
- 2023
- Full Text
- View/download PDF
122. A Recent SARS-CoV-2 Infection Enhances Antibody-Dependent Cellular Cytotoxicity against Several Omicron Subvariants following a Fourth mRNA Vaccine Dose.
- Author
-
Beaudoin-Bussières G, Tauzin A, Dionne K, Gendron-Lepage G, Medjahed H, Perreault J, Levade I, Alfadhli L, Bo Y, Bazin R, Côté M, and Finzi A
- Subjects
- Humans, SARS-CoV-2 genetics, Antibody-Dependent Cell Cytotoxicity, Spike Glycoprotein, Coronavirus genetics, Antibodies, Neutralizing, Antibodies, Viral, mRNA Vaccines, COVID-19 prevention & control
- Abstract
Since the beginning of the SARS-CoV-2 pandemic, several variants of concern (VOCs), such as the Alpha, Beta, Gamma, Delta and Omicron variants, have arisen and spread worldwide. Today, the predominant circulating subvariants are sublineages of the Omicron variant, which have more than 30 mutations in their Spike glycoprotein compared to the ancestral strain. The Omicron subvariants were significantly less recognized and neutralized by antibodies from vaccinated individuals. This resulted in a surge in the number of infections, and booster shots were recommended to improve responses against these variants. While most studies mainly measured the neutralizing activity against variants, we and others previously reported that Fc-effector functions, including antibody-dependent cellular cytotoxicity (ADCC), play an important role in humoral responses against SARS-CoV-2. In this study, we analyzed Spike recognition and ADCC activity against several Omicron subvariants by generating cell lines expressing different Omicron subvariant Spikes. We tested these responses in a cohort of donors, who were recently infected or not, before and after a fourth dose of mRNA vaccine. We showed that ADCC activity is less affected than neutralization by the antigenic shift of the tested Omicron subvariant Spikes. Moreover, we found that individuals with a history of recent infection have higher antibody binding and ADCC activity against all Omicron subvariants than people who were not recently infected. With an increase in the number of reinfections, this study helps better understand Fc-effector responses in the context of hybrid immunity.
- Published
- 2023
- Full Text
- View/download PDF
123. Cohort profile: A Québec-based plasma donor biobank to study COVID-19 immunity (PlasCoV).
- Author
-
Germain M, Lewin A, Bazin R, Dieudé M, Perreault J, Boivin A, Grégoire Y, and Renaud C
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Female, Humans, Middle Aged, Young Adult, Antibodies, Viral, Biological Specimen Banks, Blood Donors, BNT162 Vaccine, Quebec epidemiology, SARS-CoV-2, Seroepidemiologic Studies, Vaccination, Male, COVID-19 epidemiology, COVID-19 immunology, COVID-19 Vaccines immunology
- Abstract
Purpose: The long-term humoral immunity to COVID-19 is not well understood owing to the continuous emergence of new variants of concern, the evolving vaccine-induced and infection-induced immunity, and the limited duration of follow-up in previous studies. As the sole blood service in Québec (Canada), Héma-Québec established a COVID-19-focused biobank ('PlasCoV') in April 2021., Participants: As of January 2022, the biobank included 86 483 plasma samples from 15 502 regular donors (age range=18-84 years, females=49.7%), for an average of 5.6 donations per donor. Nearly two-thirds (65.6%) of biobank donors made at least two donations, with many donors having provided samples prevaccination and postvaccination (3061 (19.7%)) or preinfection and postinfection (131 (0.8%)), thus allowing for longitudinal studies on vaccine-induced and infection-induced immunity., Findings to Date: A study that used PlasCoV samples revealed that previously infected individuals who received a single dose of the BNT162b2 COVID-19 vaccine exhibited the strongest immune response. By contrast, SARS-CoV-2-naïve individuals required two vaccine doses to produce a maximal immune response. Furthermore, the results of a four-phase seroprevalence study indicated that the antinucleocapsid (N) response wanes rapidly, so that up to one-third of previously infected donors were seronegative for anti-N., Future Plans: Donations from individuals who consented to participate before 1 October 2022 will be collected up until 31 March 2023. This plasma biobank will facilitate the conduct of longitudinal studies on COVID-19 immunity, thus helping to provide valuable insights into the anti-SARS-CoV-2 immune response and its persistence, and the effects of vaccination and variants on the specificity of the anti-SARS-CoV-2 immune response., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2023
- Full Text
- View/download PDF
124. Spike recognition and neutralization of SARS-CoV-2 Omicron subvariants elicited after the third dose of mRNA vaccine.
- Author
-
Tauzin A, Nicolas A, Ding S, Benlarbi M, Medjahed H, Chatterjee D, Dionne K, Gong SY, Gendron-Lepage G, Bo Y, Perreault J, Goyette G, Gokool L, Arlotto P, Morrisseau C, Tremblay C, Martel-Laferrière V, De Serres G, Levade I, Kaufmann DE, Côté M, Bazin R, and Finzi A
- Subjects
- Humans, Vaccines, Synthetic, Mutation, Antibodies, Viral, Antibodies, Neutralizing, mRNA Vaccines, SARS-CoV-2 genetics, COVID-19 prevention & control
- Abstract
Several severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron subvariants have recently emerged, becoming the dominant circulating strains in many countries. These variants contain a large number of mutations in their spike glycoprotein, raising concerns about vaccine efficacy. In this study, we evaluate the ability of plasma from a cohort of individuals that received three doses of mRNA vaccine to recognize and neutralize these Omicron subvariant spikes. We observed that BA.4/5 and BQ.1.1 spikes are markedly less recognized and neutralized compared with the D614G and other Omicron subvariant spikes tested. Also, individuals who have been infected before or after vaccination present better humoral responses than SARS-CoV-2-naive vaccinated individuals, thus indicating that hybrid immunity generates better humoral responses against these subvariants., Competing Interests: Declaration of interests The authors declare no competing interests., (Copyright © 2023 The Author(s). Published by Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
125. Humoral Responses against BQ.1.1 Elicited after Breakthrough Infection and SARS-CoV-2 mRNA Vaccination.
- Author
-
Tauzin A, Benlarbi M, Medjahed H, Grégoire Y, Perreault J, Gendron-Lepage G, Gokool L, Morrisseau C, Arlotto P, Tremblay C, Kaufmann DE, Martel-Laferrière V, Levade I, Côté M, De Serres G, Bazin R, and Finzi A
- Abstract
The Omicron BQ.1.1 variant is now the major SARS-CoV-2 circulating strain in many countries. Because of the many mutations present in its Spike glycoprotein, this variant is resistant to humoral responses elicited by monovalent mRNA vaccines. With the goal to improve immune responses against Omicron subvariants, bivalent mRNA vaccines have recently been approved in several countries. In this study, we measure the capacity of plasma from vaccinated individuals, before and after a fourth dose of mono- or bivalent mRNA vaccine, to recognize and neutralize the ancestral (D614G) and the BQ.1.1 Spikes. Before and after the fourth dose, we observe a significantly better recognition and neutralization of the ancestral Spike. We also observe that fourth-dose vaccinated individuals who have been recently infected better recognize and neutralize the BQ.1.1 Spike, independently of the mRNA vaccine used, than donors who have never been infected or have an older infection. Our study supports that hybrid immunity, generated by vaccination and a recent infection, induces higher humoral responses than vaccination alone, independently of the mRNA vaccine used.
- Published
- 2023
- Full Text
- View/download PDF
126. The Fc-effector function of COVID-19 convalescent plasma contributes to SARS-CoV-2 treatment efficacy in mice.
- Author
-
Ullah I, Beaudoin-Bussières G, Symmes K, Cloutier M, Ducas E, Tauzin A, Laumaea A, Grunst MW, Dionne K, Richard J, Bégin P, Mothes W, Kumar P, Bazin R, Finzi A, and Uchil PD
- Subjects
- Animals, Mice, COVID-19 Serotherapy, Treatment Outcome, Immunoglobulin G, SARS-CoV-2, COVID-19 therapy
- Abstract
COVID-19 convalescent plasmas (CCPs) are chosen for plasma therapy based on neutralizing titers and anti-Spike immunoglobulin levels. However, CCP characteristics that promote SARS-CoV-2 control are complex and incompletely defined. Using an in vivo imaging approach, we demonstrate that CCPs with low neutralizing (ID
50 ≤ 1:250), but moderate to high Fc-effector activity, in contrast to those with poor Fc function, delay mortality and/or improve survival of SARS-CoV-2-challenged K18-hACE2 mice. The impact of innate immune cells on CCP efficacy depended on their residual neutralizing activity. Fractionation of a selected CCP revealed that IgG and Ig(M + A) were required during therapy, but the IgG fraction alone sufficed during prophylaxis. Finally, despite reduced neutralization, ancestral SARS-CoV-2-elicited CCPs significantly delayed Delta and Beta-induced mortality suggesting that Fc-effector functions contribute to immunity against VOCs. Thus, Fc activity of CCPs provide a second line of defense when neutralization is compromised and can serve as an important criterion for CCP selection., Competing Interests: Declaration of interests The authors declare no competing interests., (Copyright © 2022 The Author(s). Published by Elsevier Inc. All rights reserved.)- Published
- 2023
- Full Text
- View/download PDF
127. Assessment of the soluble proteins HMGB1, CD40L and CD62P during various platelet preparation processes and the storage of platelet concentrates: The BEST collaborative study.
- Author
-
Cognasse F, Hamzeh Cognasse H, Eyraud MA, Prier A, Arthaud CA, Tiberghien P, Begue S, de Korte D, Gouwerok E, Greinacher A, Aurich K, Noorman F, Dumont L, Kelly K, Cloutier M, Bazin R, Cardigan R, Huish S, Smethurst P, Devine D, Schubert P, Johnson L, and Marks DC
- Subjects
- Humans, Blood Platelets metabolism, Blood Preservation methods, CD40 Ligand metabolism, Platelet Transfusion, Blood Component Removal methods, HMGB1 Protein metabolism
- Abstract
Background: Structural and biochemical changes in stored platelets are influenced by collection and processing methods. This international study investigates the effects of platelet (PLT) processing and storage conditions on HMGB1, sCD40L, and sCD62P protein levels in platelet concentrate supernatants (PCs)., Study Design/methods: PC supernatants (n = 3748) were collected by each international centre using identical centrifugation methods (n = 9) and tested centrally using the ELISA/Luminex platform. Apheresis versus the buffy coat (BC-PC) method, plasma storage versus PAS and RT storage versus cold (4°C) were investigated. We focused on PC preparation collecting samples during early (RT: day 1-3; cold: day 1-5) and late (RT: day 4-7; cold: day 7-10) storage time points., Results: HMGB1, sCD40L, and sCD62P concentrations were similar during early storage periods, regardless of storage solution (BC-PC plasma and BC-PC PAS-E) or temperature. During storage and without PAS, sCD40L and CD62P in BC-PC supernatants increased significantly (+33% and +41%, respectively) depending on storage temperature (22 vs. 4°C). However, without PAS-E, levels decreased significantly (-31% and -20%, respectively), depending on storage temperature (22 vs. 4°C). Contrastingly, the processing method appeared to have greater impact on HMGB1 release versus storage duration. These data highlight increases in these parameters during storage and differences between preparation methods and storage temperatures., Conclusions: The HMGB1 release mechanism/intracellular pathways appear to differ from sCD62P and sCD40L. The extent to which these differences affect patient outcomes, particularly post-transfusion platelet increment and adverse events, warrants further investigation in clinical trials with various therapeutic indications., (© 2022 AABB.)
- Published
- 2023
- Full Text
- View/download PDF
128. A boost with SARS-CoV-2 BNT162b2 mRNA vaccine elicits strong humoral responses independently of the interval between the first two doses.
- Author
-
Tauzin A, Gong SY, Chatterjee D, Ding S, Painter MM, Goel RR, Beaudoin-Bussières G, Marchitto L, Boutin M, Laumaea A, Okeny J, Gendron-Lepage G, Bourassa C, Medjahed H, Goyette G, Williams JC, Bo Y, Gokool L, Morrisseau C, Arlotto P, Bazin R, Fafard J, Tremblay C, Kaufmann DE, De Serres G, Richard J, Côté M, Duerr R, Martel-Laferrière V, Greenplate AR, Wherry EJ, and Finzi A
- Subjects
- Humans, SARS-CoV-2, BNT162 Vaccine, Antibodies, Viral, COVID-19 Vaccines, Vaccination, mRNA Vaccines, COVID-19 prevention & control, Viral Vaccines
- Abstract
Due to the recrudescence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections worldwide, mainly caused by the Omicron variant of concern (VOC) and its sub-lineages, several jurisdictions are administering an mRNA vaccine boost. Here, we analyze humoral responses induced after the second and third doses of an mRNA vaccine in naive and previously infected donors who received their second dose with an extended 16-week interval. We observe that the extended interval elicits robust humoral responses against VOCs, but this response is significantly diminished 4 months after the second dose. Administering a boost to these individuals brings back the humoral responses to the same levels obtained after the extended second dose. Interestingly, we observe that administering a boost to individuals that initially received a short 3- to 4-week regimen elicits humoral responses similar to those observed in the long interval regimen. Nevertheless, humoral responses elicited by the boost in naive individuals do not reach those present in previously infected vaccinated individuals., Competing Interests: Declaration of interests A.R.G. is a consultant for Relation Therapeutics. E.J.W. is consulting for or is an advisor for Merck, Marengo, Janssen, Related Sciences, Synthekine, and Surface Oncology. E.J.W. is a founder of Surface Oncology, Danger Bio, and Arsenal Biosciences., (Copyright © 2022 The Author(s). Published by Elsevier Inc. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
129. Blood Endothelial-Cell Extracellular Vesicles as Potential Biomarkers for the Selection of Plasma in COVID-19 Convalescent Plasma Therapy.
- Author
-
Amri N, Tessier N, Bégin R, Vachon L, Bégin P, Bazin R, Loubaki L, and Martel C
- Subjects
- Betacoronavirus, Biomarkers, Cytokines, Endothelial Cells, Humans, Immunization, Passive, Inflammation, Pandemics, COVID-19 Serotherapy, COVID-19 therapy, Coronavirus Infections, Extracellular Vesicles, Pneumonia, Viral
- Abstract
Despite the advancement of vaccination and therapies currently available, deaths due to the coronavirus disease 2019 (COVID-19) are still heavily documented. Severely infected individuals experience a generalized inflammatory storm, caused by massive secretion of pro-inflammatory cytokines that can lead to endothelial dysfunction, cardiovascular disease, multi-organ failure, and even death. COVID-19 convalescent plasma (CCP) therapy, selected primarily based on anti-SARS-CoV-2 antibody levels, has not been as convincing as expected in the fight against COVID-19. Given the consequences of a dysfunctional endothelium on the progression of the disease, we propose that the selection of plasma for CCP therapy should be based on more specific parameters that take into consideration the effect on vascular inflammation. Thus, in the present study, we have characterized a subset of CCP that have been used for CCP therapy and measured their anti- or pro-inflammatory effect on human coronary artery endothelial cells (HCAECs). Our data revealed that the longer the time lapse between the onset of symptoms and the plasma donation, the more mitochondrial dysfunction can be evidenced. The concentration of blood endothelial cell extracellular vesicles (BEC-EVs) was increased in the plasma of young individuals with mild symptoms. This type of selected convalescent plasma promoted the activation of the blood vascular endothelium, as reflected by the overexpression of ICAM1 and NFκB1 and the downregulation of VE-Cadherin. We propose this mechanism is a warning signal sent by the injured endothelium to trigger self-defense of peripheral blood vessels against excessive inflammation. Therefore, these results are in line with our previous data. They suggest that a more specific selection of COVID-19 convalescent plasma should be based on the time of donation following the onset of the clinical symptoms of the donor, the severity of the symptoms, and the age of the donor. These characteristics are relatively easy to identify in any hospital and would reflect the concentration of plasma BEC-EVs and be optimal in CCP therapy.
- Published
- 2022
- Full Text
- View/download PDF
130. Humoral immune responses against SARS-CoV-2 Spike variants after mRNA vaccination in solid organ transplant recipients.
- Author
-
Tauzin A, Beaudoin-Bussières G, Gong SY, Chatterjee D, Gendron-Lepage G, Bourassa C, Goyette G, Racine N, Khrifi Z, Turgeon J, Tremblay C, Martel-Laferrière V, Kaufmann DE, Cardinal H, Cloutier M, Bazin R, Duerr R, Dieudé M, Hébert MJ, and Finzi A
- Abstract
Although SARS-CoV-2 mRNA vaccination has been shown to be safe and effective in the general population, immunocompromised solid organ transplant recipients (SOTRs) were reported to have impaired immune responses after one or two doses of vaccine. In this study, we examined humoral responses induced after the second and the third dose of mRNA vaccine in different SOTR (kidney, liver, lung, and heart). Compared to a cohort of SARS-CoV-2 naïve immunocompetent health care workers (HCWs), the second dose induced weak humoral responses in SOTRs, except for the liver recipients. The third dose boosted these responses but they did not reach the same level as in HCW. Interestingly, although the neutralizing activity against Delta and Omicron variants remained very low after the third dose, Fc-mediated effector functions in SOTR reached similar levels as in the HCW cohort. Whether these responses will suffice to protect SOTR from severe outcome remains to be determined., Competing Interests: The authors declare no competing interests., (© 2022 The Authors.)
- Published
- 2022
- Full Text
- View/download PDF
131. COVID-19 vaccine humoral response in frequent platelet donors with plateletpheresis-associated lymphopenia.
- Author
-
Laumaea AE, Lewin A, Chatterjee D, Marchitto L, Ding S, Gendron-Lepage G, Goyette G, Allard MÈ, Simard C, Tremblay T, Perreault J, Duerr R, Finzi A, and Bazin R
- Subjects
- Blood Donors, Humans, Platelet Count, Plateletpheresis methods, COVID-19 prevention & control, COVID-19 therapy, COVID-19 Vaccines adverse effects, Lymphopenia etiology
- Abstract
Background: Plateletpheresis involves platelet separation and collection from whole blood while other blood cells are returned to the donor. Because platelets are replaced faster than red blood cells, as many as 24 donations can be done annually. However, some frequent apheresis platelet donors (>20 donations annually) display severe plateletpheresis-associated lymphopenia; in particular, CD4
+ T but not B cell numbers are decreased. COVID-19 vaccination thereby provides a model to assess whether lymphopenic platelet donors present compromised humoral immune responses., Study Design and Methods: We assessed vaccine responses following 2 doses of COVID-19 vaccination in a cohort of 43 plateletpheresis donors with a range of pre-vaccination CD4+ T cell counts (76-1537 cells/μl). In addition to baseline T cell measurements, antibody binding assays to full-length Spike and the Receptor Binding Domain (RBD) were performed pre- and post-vaccination. Furthermore, pseudo-particle neutralization and antibody-dependent cellular cytotoxicity assays were conducted to measure antibody functionality., Results: Participants were stratified into two groups: <400 CD4/μl (n = 27) and ≥ 400 CD4/μl (n = 16). Following the first dose, 79% seroconverted within the <400 CD4/μl group compared to 87% in the ≥400 CD4/μl group; all donors were seropositive post-second dose with significant increases in antibody levels. Importantly differences in CD4+ T cell levels minimally impacted neutralization, Spike recognition, and IgG Fc-mediated effector functions., Discussion: Overall, our results indicate that lymphopenic plateletpheresis donors do not exhibit significant immune dysfunction; they have retained the T and B cell functionality necessary for potent antibody responses after vaccination., (© 2022 AABB.)- Published
- 2022
- Full Text
- View/download PDF
132. Cultured Autologous Corneal Epithelia for the Treatment of Unilateral Limbal Stem Cell Deficiency: A Case Series of 15 Patients.
- Author
-
Guérin LP, Larouche D, Morcos MW, Faucher A, Auger FA, Knoppers BM, Kyrillos R, Bazin R, and Germain L
- Abstract
Damage to limbal epithelial stem cells can lead to limbal stem cell deficiency (LSCD). Current autologous treatment procedures for unilateral LSCD bear a significant risk of inducing LSCD in the donor eye. This complication can be avoided by grafting a stem cell containing cultured autologous corneal epithelium (CACE). The primary objective of this study was to demonstrate the safety of CACE grafted on eyes with LSCD. The secondary objective was to assess the efficacy of a CACE graft in restoring a self-renewing corneal surface with adequate anatomic structures, as well as improving the best corrected visual acuity (BCVA). Fifteen patients were grafted with a CACE on a fibrin gel produced from a 3 mm
2 limbal biopsy harvested from the donor eye. Data were collected at baseline and after grafting. Follow-ups from 1 to 5 years were conducted. No major adverse events related to the CACE graft were observed. For every visit, an anatomic score based on corneal opacity as well as central vascularization and a functional score based on BCVA were determined. Safety was demonstrated by the low occurrence of complications. Anatomical (93%) and functional (47%) results are promising for improving vision in LSCD patients. Combined functional success and partial success rates with inclusion of BCVA were 53% [CI95: 27-79%] one year after CACE grafting. At the last follow-up, 87% [CI95: 60-98%] of the patients had attained corneal clarity. The outcomes demonstrate the safety of our technique and are promising regarding the efficacy of CACE in these patients.- Published
- 2022
- Full Text
- View/download PDF
133. Multicenter evaluation of the IL-3-pSTAT5 assay to assess the potency of cryopreserved stem cells from cord blood units: The BEST Collaborative study.
- Author
-
Trépanier P, Fournier D, Simard C, Fontaine MJ, Stroncek D, Takanashi M, McKenna D, Schwartz J, Tanhehco YC, Reems JA, Torrents S, Kogler G, Liedtke S, Giroux M, Holovati JL, Louis I, Prasath A, Pineault N, and Bazin R
- Subjects
- Blood Banking methods, Colony-Forming Units Assay, Humans, STAT5 Transcription Factor metabolism, Stem Cells, Fetal Blood, Interleukin-3
- Abstract
Background: The IL-3-pSTAT5 assay, a new, rapid, and standardized flow-cytometry-based assay may compensate for several limitations of the colony-forming unit (CFU) assay typically used for stem cell potency assessments of cord blood units (CBU). We performed an inter-laboratory evaluation of the performance of this new assay., Study Design and Methods: This Biomedical Excellence for Safer Transfusion (BEST) Collaborative multicenter, international study included 15 participants from public cord blood banks (CBBs), CBB-supporting research laboratories, and stem cell laboratories. To perform the IL-3-pSTAT5 assay, participating centers received reagents, instructions, and 10 blind CBU samples, including eight normal samples and two samples exposed to a transient warming event. We measured inter-laboratory agreement qualitatively (proportion of correctly classified samples) and quantitatively (coefficient of variation [CV], correlation coefficients, receiver operating characteristics (ROC) curve, and intraclass correlation coefficient [ICC])., Results: The qualitative agreement was 97.3% (i.e., 107/110; Fleiss' kappa = 0.835). The average CV on a per-sample basis was 11.57% among all samples, 8.99% among normal samples, and on a per-center basis was 9.42% among normal samples. In a correlation matrix that compared results across centers, the mean Pearson's correlation coefficient was 0.88 (standard deviation = 0.04). The ICC was 0.83 (95% confidence interval = 0.68-0.95). The area under the curve (AUC) from the ROC curve was 0.9974., Discussion: Excellent qualitative and quantitative agreement was exhibited across laboratories. The IL-3-pSTAT5 assay may therefore be implemented in flow cytometry laboratories to rapidly and reliably provide standardized measures of stem cell potency in CBUs., (© 2022 AABB.)
- Published
- 2022
- Full Text
- View/download PDF
134. Production and Quality Assurance of Human Polyclonal Hyperimmune Immunoglobulins Against SARS-CoV-2.
- Author
-
Burnouf T, Gathof B, Bloch EM, Bazin R, de Angelis V, Patidar GK, Rastvorceva RMG, Oreh A, Goel R, Rahimi-Levene N, Hindawi S, Al-Riyami AZ, and So-Osman C
- Subjects
- Antibodies, Humans, Immunization, Passive, Pandemics, COVID-19 Serotherapy, COVID-19 therapy, SARS-CoV-2
- Abstract
The coronavirus disease 2019 (COVID-19) pandemic has highlighted the potential therapeutic value of early passive polyclonal immunotherapy using high-titer convalescent plasma (CCP). Human polyclonal hyperimmune immunoglobulin (HIG) has several advantages over CCP. Unlike CCP, HIG can provide standardized and controlled antibody content. It is also subjected to robust pathogen reduction rendering it virally safe and is purified by technologies demonstrated to preserve immunoglobulin neutralization capacity and Fc fragment integrity. This document provides an overview of current practices and guidance for the collection and testing of plasma rich in antibodies against Severe Acute Respiratory Coronavirus 2 (SARS-CoV-2) and its industrial fractionation for the manufacture of quality-assured and safe HIG. Considerations are also given to the production of HIG preparations in low- and middle-income countries., (Copyright © 2022 Elsevier Inc. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
135. Seroprevalence of SARS-CoV-2 antibodies among blood donors in Québec: an update from a serial cross-sectional study.
- Author
-
Lewin A, De Serres G, Grégoire Y, Perreault J, Drouin M, Fournier MJ, Tremblay T, Beaudoin J, Boivin A, Goyette G, Finzi A, Bazin R, Germain M, Delage G, and Renaud C
- Subjects
- Antibodies, Viral, Blood Donors, COVID-19 Testing, Cross-Sectional Studies, Female, Humans, Male, Middle Aged, Quebec epidemiology, Seroepidemiologic Studies, COVID-19 epidemiology, SARS-CoV-2
- Abstract
Objectives: We previously estimated the seroprevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies following the first pandemic wave at 2.23% in Québec, Canada. Following the much bigger second wave in fall 2020 and early 2021, we estimated the seroprevalence of anti-SARS-CoV-2 in Québec during the first months of 2021., Methods: Blood samples from regular, asymptomatic (for ≥ 14 days) donors were collected between January 25, 2021 and March 11, 2021. Anti-SARS-CoV-2 seropositivity was assessed using an enzyme-linked immunosorbent assay that captures antibodies directed against the receptor binding domain of the SARS-CoV-2 spike (and hence cannot discriminate between infection- and vaccine-induced seropositivity). Seroprevalence estimates were adjusted for regional distribution, age, and sex., Results: Samples from 7924 eligible donors were analyzed, including 620 (7.8%) vaccinated donors and 7046 (88.9%) unvaccinated donors (vaccination status unknown for 258 (3.3%) donors). Overall, median age was 51 years; 46.4% of donors were female. The adjusted seroprevalence was 10.5% (95% CI = 9.7-11.3) in the unvaccinated population and 14.7% (95% CI = 13.8-15.6) in the overall population. Seroprevalence gradually decreased with age and was higher among donors who self-identified as having a racial/ethnic background other than white, both in the overall and in the unvaccinated populations., Conclusion: The seroprevalence of SARS-CoV-2 antibodies significantly increased in Québec since spring 2020, with younger persons and ethnic minorities being disproportionately affected. When compared with the cumulative incidence rate reported by public health authorities (i.e., 3.3% as of March 11, 2021), these results suggest that a substantial proportion of infections remain undetected despite improvements in access to COVID-19 testing., (© 2022. The Author(s) under exclusive license to The Canadian Public Health Association.)
- Published
- 2022
- Full Text
- View/download PDF
136. International Society of Blood Transfusion survey of experiences of blood banks and transfusion services during the COVID-19 pandemic.
- Author
-
Al-Riyami AZ, Burnouf T, Wood EM, Devine DV, Oreh A, Apelseth TO, Goel R, Bloch EM, van Den Berg K, Getshen M, Louw V, Ang AL, Lee CK, Rahimi-Levene N, Stramer SL, Vassallo R, Schulze TJ, Patidar GK, Pandey HC, Dubey R, Badawi M, Hindawi S, Meshi A, Matsushita T, Sorrentino E, Grubovic Rastvorceva RM, Bazin R, Vermeulen M, Nahirniak S, Tsang HC, Vrielink H, Triyono T, Addas-Carvalho M, Hećimović A, Torres OW, Mutindu SM, Bengtsson J, Dominguez D, Sayedahmed A, Hanisa Musa R, Gautam B, Herczenik E, and So-Osman C
- Subjects
- Blood Banks, Blood Donors, Blood Transfusion, Humans, Immunization, Passive, Surveys and Questionnaires, COVID-19 Serotherapy, COVID-19 epidemiology, COVID-19 therapy, Pandemics
- Abstract
Background and Objectives: The coronavirus disease 2019 (COVID-19) pandemic has impacted blood systems worldwide. Challenges included maintaining blood supplies and initiating the collection and use of COVID-19 convalescent plasma (CCP). Sharing information on the challenges can help improve blood collection and utilization., Materials and Methods: A survey questionnaire was distributed to International Society of Blood Transfusion members in 95 countries. We recorded respondents' demographic information, impacts on the blood supply, CCP collection and use, transfusion demands and operational challenges., Results: Eighty-two responses from 42 countries, including 24 low- and middle-income countries, were analysed. Participants worked in national (26.8%) and regional (26.8%) blood establishments and hospital-based (42.7%) institutions. CCP collection and transfusion were reported by 63% and 36.6% of respondents, respectively. Decreases in blood donations occurred in 70.6% of collecting facilities. Despite safety measures and recruitment strategies, donor fear and refusal of institutions to host blood drives were major contributing factors. Almost half of respondents working at transfusion medicine services were from large hospitals with over 10,000 red cell transfusions per year, and 76.8% of those hospitals experienced blood shortages. Practices varied in accepting donors for blood or CCP donations after a history of COVID-19 infection, CCP transfusion, or vaccination. Operational challenges included loss of staff, increased workloads and delays in reagent supplies. Almost half of the institutions modified their disaster plans during the pandemic., Conclusion: The challenges faced by blood systems during the COVID-19 pandemic highlight the need for guidance, harmonization, and strengthening of the preparedness and the capacity of blood systems against future infectious threats., (© 2022 International Society of Blood Transfusion.)
- Published
- 2022
- Full Text
- View/download PDF
137. Use of Early Donated COVID-19 Convalescent Plasma Is Optimal to Preserve the Integrity of Lymphatic Endothelial Cells.
- Author
-
Amri N, Bégin R, Tessier N, Vachon L, Villeneuve L, Bégin P, Bazin R, Loubaki L, and Martel C
- Abstract
Convalescent plasma therapy (CPT) has gained significant attention since the onset of the coronavirus disease 2019 (COVID-19) pandemic. However, clinical trials designed to study the efficacy of CPT based on antibody concentrations were inconclusive. Lymphatic transport is at the interplay between the immune response and the resolution of inflammation from peripheral tissues, including the artery wall. As vascular complications are a key pathogenic mechanism in COVID-19, leading to inflammation and multiple organ failure, we believe that sustaining lymphatic vessel function should be considered to define optimal CPT. We herein sought to determine what specific COVID-19 convalescent plasma (CCP) characteristics should be considered to limit inflammation-driven lymphatic endothelial cells (LEC) dysfunction. CCP donated 16 to 100 days after the last day of symptoms was characterized and incubated on inflammation-elicited adult human dermal LEC (aHDLEC). Plasma analysis revealed that late donation correlates with higher concentration of circulating pro-inflammatory cytokines. Conversely, extracellular vesicles (EVs) derived from LEC are more abundant in early donated plasma (r = -0.413, p = 0.004). Thus, secretion of LEC-EVs by an impaired endothelium could be an alarm signal that instigate the self-defense of peripheral lymphatic vessels against an excessive inflammation. Indeed, in vitro experiments suggest that CCP obtained rapidly following the onset of symptoms does not damage the aHDLEC junctions as much as late-donated plasma. We identified a particular signature of CCP that would counteract the effects of an excessive inflammation on the lymphatic endothelium. Accordingly, an easy and efficient selection of convalescent plasma based on time of donation would be essential to promote the preservation of the lymphatic and immune system of infected patients.
- Published
- 2022
- Full Text
- View/download PDF
138. Evolution of Anti-RBD IgG Avidity following SARS-CoV-2 Infection.
- Author
-
Tauzin A, Gendron-Lepage G, Nayrac M, Anand SP, Bourassa C, Medjahed H, Goyette G, Dubé M, Bazin R, Kaufmann DE, and Finzi A
- Subjects
- Antibodies, Viral, Humans, Immunoglobulin G, Protein Binding, SARS-CoV-2 genetics, COVID-19
- Abstract
SARS-CoV-2 infection rapidly elicits anti-Spike antibodies whose quantity in plasma gradually declines upon resolution of symptoms. This decline is part of the evolution of an immune response leading to B cell differentiation into short-lived antibody-secreting cells or resting memory B cells. At the same time, the ongoing class switch and antibody maturation processes occurring in germinal centers lead to the selection of B cell clones secreting antibodies with higher affinity for their cognate antigen, thereby improving their functional activity. To determine whether the decline in SARS-CoV-2 antibodies is paralleled with an increase in avidity of the anti-viral antibodies produced, we developed a simple assay to measure the avidity of anti-receptor binding domain (RBD) IgG elicited by SARS-CoV-2 infection. We longitudinally followed a cohort of 29 convalescent donors with blood samples collected between 6- and 32-weeks post-symptoms onset. We observed that, while the level of antibodies declines over time, the anti-RBD avidity progressively increases and correlates with the B cell class switch. Additionally, we observed that anti-RBD avidity increased similarly after SARS-CoV-2 mRNA vaccination and after SARS-CoV-2 infection. Our results suggest that anti-RBD IgG avidity determination could be a surrogate assay for antibody affinity maturation and, thus, suitable for studying humoral responses elicited by natural infection and/or vaccination.
- Published
- 2022
- Full Text
- View/download PDF
139. SARS-CoV-2 Omicron Spike recognition by plasma from individuals receiving BNT162b2 mRNA vaccination with a 16-week interval between doses.
- Author
-
Chatterjee D, Tauzin A, Marchitto L, Gong SY, Boutin M, Bourassa C, Beaudoin-Bussières G, Bo Y, Ding S, Laumaea A, Vézina D, Perreault J, Gokool L, Morrisseau C, Arlotto P, Fournier É, Guilbault A, Delisle B, Levade I, Goyette G, Gendron-Lepage G, Medjahed H, De Serres G, Tremblay C, Martel-Laferrière V, Kaufmann DE, Bazin R, Prévost J, Moreira S, Richard J, Côté M, and Finzi A
- Subjects
- Adult, Aged, Antibodies, Neutralizing analysis, Antibodies, Neutralizing immunology, Antibodies, Viral analysis, Antibodies, Viral blood, Antibodies, Viral immunology, BNT162 Vaccine immunology, Cohort Studies, Female, HEK293 Cells, Humans, Immunization, Secondary methods, Male, Middle Aged, Quebec, SARS-CoV-2 pathogenicity, Time Factors, Vaccination methods, Vaccine Potency, Vaccines, Synthetic administration & dosage, Vaccines, Synthetic immunology, Young Adult, mRNA Vaccines administration & dosage, mRNA Vaccines immunology, Antibodies, Neutralizing blood, BNT162 Vaccine administration & dosage, Immunization Schedule, SARS-CoV-2 immunology, Spike Glycoprotein, Coronavirus immunology
- Abstract
Continuous emergence of SARS-CoV-2 variants of concern (VOCs) is fueling the COVID-19 pandemic. Omicron (B.1.1.529) rapidly spread worldwide. The large number of mutations in its Spike raise concerns about a major antigenic drift that could significantly decrease vaccine efficacy and infection-induced immunity. A long interval between BNT162b2 mRNA doses elicits antibodies that efficiently recognize Spikes from different VOCs. Here, we evaluate the recognition of Omicron Spike by plasma from a cohort of SARS-CoV-2 naive and previously infected individuals who received their BNT162b2 mRNA vaccine 16 weeks apart. Omicron Spike is recognized less efficiently than D614G, Alpha, Beta, Gamma, and Delta Spikes. We compare with plasma activity from participants receiving a short (4 weeks) interval regimen. Plasma from individuals of the long-interval cohort recognize and neutralize better the Omicron Spike compared with those who received a short interval. Whether this difference confers any clinical benefit against Omicron remains unknown., Competing Interests: Declaration of interests A.F. has filed a provisional patent application on the anti-Spike monoclonal antibody CV3-25., (Copyright © 2022 The Author(s). Published by Elsevier Inc. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
140. Standardization of a flow cytometry SARS-CoV-2 serologic test.
- Author
-
Simard C, Richard J, Bazin R, Finzi A, and Trépanier P
- Abstract
The SARS-CoV-2 virus is the causing agent of the coronavirus disease 2019 (COVID-19) pandemic responsible for millions of deaths worldwide. The development of the humoral response to the virus has been the subject of intensive research. A flow cytometry-based assay using native full-length SARS-CoV-2 Spike protein expressed in 293 T cells was recently proposed as a complementary seropositivity assay. The aim of our study was to further develop the flow cytometry assay and to standardize its parameters for reliable inter-laboratory use. We have optimized the protocol, established the Receiving Operating Characteristic (ROC) curve and tested reproducibility using pre-COVID and convalescent, SARS-CoV-2 individual plasma samples. The flow-based assay was simplified and standardized by cultivating the 293 T cells in suspension and expressing results in Mean Equivalent Soluble Fluorochrome (MESF) using an internal antibody positive control. The ROC curve was determined with an area under the curve (AUC) of 0.996 and the assay specificity and sensitivity were established at 100% and 97.7% respectively. Reproducibility was good as determined on multiple cytometers, on different days, and with data acquisition as far as 72 h post-staining. The standardized assay could be used as a high throughput confirmatory assay in flow cytometry laboratories involved in serological testing., Supplementary Information: The online version contains supplementary material available at 10.1007/s10616-021-00511-1., (© The Author(s), under exclusive licence to Springer Nature B.V. 2021.)
- Published
- 2022
- Full Text
- View/download PDF
141. Strong humoral immune responses against SARS-CoV-2 Spike after BNT162b2 mRNA vaccination with a 16-week interval between doses.
- Author
-
Tauzin A, Gong SY, Beaudoin-Bussières G, Vézina D, Gasser R, Nault L, Marchitto L, Benlarbi M, Chatterjee D, Nayrac M, Laumaea A, Prévost J, Boutin M, Sannier G, Nicolas A, Bourassa C, Gendron-Lepage G, Medjahed H, Goyette G, Bo Y, Perreault J, Gokool L, Morrisseau C, Arlotto P, Bazin R, Dubé M, De Serres G, Brousseau N, Richard J, Rovito R, Côté M, Tremblay C, Marchetti GC, Duerr R, Martel-Laferrière V, Kaufmann DE, and Finzi A
- Subjects
- Adult, Aged, Antibodies, Neutralizing immunology, Antibodies, Viral immunology, COVID-19 virology, Female, Humans, Male, Middle Aged, Vaccination methods, Young Adult, BNT162 Vaccine immunology, COVID-19 immunology, COVID-19 Vaccines immunology, Immunity, Humoral immunology, SARS-CoV-2 immunology, Spike Glycoprotein, Coronavirus immunology, Vaccines, Synthetic immunology, mRNA Vaccines immunology
- Abstract
The standard regimen of the BNT162b2 mRNA vaccine for SARS-CoV-2 includes two doses administered three weeks apart. However, some public health authorities spaced these doses, raising questions about efficacy. We analyzed longitudinal humoral responses against the D614G strain and variants of concern for SARS-CoV-2 in a cohort of SARS-CoV-2-naive and previously infected individuals who received the BNT162b2 mRNA vaccine with sixteen weeks between doses. While administering a second dose to previously infected individuals did not significantly improve humoral responses, these responses significantly increased in naive individuals after a 16-week spaced second dose, achieving similar levels as in previously infected individuals. Comparing these responses to those elicited in individuals receiving a short (4-week) dose interval showed that a 16-week interval induced more robust responses among naive vaccinees. These findings suggest that a longer interval between vaccine doses does not compromise efficacy and may allow greater flexibility in vaccine administration., Competing Interests: Declaration of interests The authors declare no competing interests., (Copyright © 2021 Elsevier Inc. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
142. Author Correction: Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial.
- Author
-
Bégin P, Callum J, Jamula E, Cook R, Heddle NM, Tinmouth A, Zeller MP, Beaudoin-Bussières G, Amorim L, Bazin R, Loftsgard KC, Carl R, Chassé M, Cushing MM, Daneman N, Devine DV, Dumaresq J, Fergusson DA, Gabe C, Glesby MJ, Li N, Liu Y, McGeer A, Robitaille N, Sachais BS, Scales DC, Schwartz L, Shehata N, Turgeon AF, Wood H, Zarychanski R, Finzi A, and Arnold DM
- Published
- 2022
- Full Text
- View/download PDF
143. International Forum on the Collection and Use of COVID-19 Convalescent Plasma: Protocols, Challenges and Lessons Learned: Summary.
- Author
-
Al-Riyami AZ, Burnouf T, Yazer M, Triulzi D, Kumaş LT, Sağdur L, Pelit NB, Bazin R, Hindawi SI, Badawi MA, Patidar GK, Pandey HC, Chaurasia R, Fachini RM, Scuracchio P, Wendel S, Ang AL, Ong KH, Young P, Ihalainen J, Vierikko A, Qiu Y, Yang R, Xu H, Rahimi-Levene N, Shinar E, Izak M, Gonzalez CA, Ferrari DM, Cini PV, Aditya RN, Sharma RR, Sachdev S, Hans R, Lamba DS, Nissen-Meyer LSH, Devine DV, Lee CK, Leung JN, Hung IFN, Tiberghien P, Gallian P, Morel P, Al Maamari K, Al-Hinai Z, Vrielink H, So-Osman C, De Angelis V, Berti P, Ostuni A, Marano G, Nevessignsky MT, El Ekiaby M, Daly J, Hoad V, Kim S, van den Berg K, Vermeulen M, Glatt TN, Schäfer R, Reik R, Gammon R, Lopez M, Estcourt L, MacLennan S, Roberts D, Louw V, and Dunbar N
- Subjects
- Humans, Immunization, Passive, SARS-CoV-2, COVID-19 Serotherapy, COVID-19 therapy, Coronavirus Infections
- Published
- 2021
- Full Text
- View/download PDF
144. International Forum on the Collection and Use of COVID-19 Convalescent Plasma: Responses.
- Author
-
Al-Riyami AZ, Burnouf T, Yazer M, Triulzi D, Kumaş LT, Sağdur L, Pelit NB, Bazin R, Hindawi SI, Badawi MA, Patidar GK, Pandey HC, Chaurasia R, Fachini RM, Scuracchio P, Wendel S, Ang AL, Ong KH, Young P, Ihalainen J, Vierikko A, Qiu Y, Yang R, Xu H, Rahimi-Levene N, Shinar E, Izak M, Gonzalez CA, Ferrari DM, Cini PV, Aditya RN, Sharma RR, Sachdev S, Hans R, Lamba DS, Nissen-Meyer LSH, Devine DV, Lee CK, Leung JN, Hung IFN, Tiberghien P, Gallian P, Morel P, Al Maamari K, Al-Hinai Z, Vrielink H, So-Osman C, De Angelis V, Berti P, Ostuni A, Marano G, Nevessignsky MT, El Ekiaby M, Daly J, Hoad V, Kim S, van den Berg K, Vermeulen M, Glatt TN, Schäfer R, Reik R, Gammon R, Lopez M, Estcourt L, MacLennan S, Roberts D, Louw V, and Dunbar N
- Published
- 2021
- Full Text
- View/download PDF
145. Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial.
- Author
-
Bégin P, Callum J, Jamula E, Cook R, Heddle NM, Tinmouth A, Zeller MP, Beaudoin-Bussières G, Amorim L, Bazin R, Loftsgard KC, Carl R, Chassé M, Cushing MM, Daneman N, Devine DV, Dumaresq J, Fergusson DA, Gabe C, Glesby MJ, Li N, Liu Y, McGeer A, Robitaille N, Sachais BS, Scales DC, Schwartz L, Shehata N, Turgeon AF, Wood H, Zarychanski R, Finzi A, and Arnold DM
- Subjects
- Adult, Aged, Aged, 80 and over, Brazil epidemiology, COVID-19 epidemiology, Canada epidemiology, Female, Hospitalization statistics & numerical data, Humans, Immunization, Passive, Intention to Treat Analysis, Male, Middle Aged, SARS-CoV-2 immunology, Treatment Outcome, United States epidemiology, COVID-19 Serotherapy, COVID-19 therapy
- Abstract
The efficacy of convalescent plasma for coronavirus disease 2019 (COVID-19) is unclear. Although most randomized controlled trials have shown negative results, uncontrolled studies have suggested that the antibody content could influence patient outcomes. We conducted an open-label, randomized controlled trial of convalescent plasma for adults with COVID-19 receiving oxygen within 12 d of respiratory symptom onset ( NCT04348656 ). Patients were allocated 2:1 to 500 ml of convalescent plasma or standard of care. The composite primary outcome was intubation or death by 30 d. Exploratory analyses of the effect of convalescent plasma antibodies on the primary outcome was assessed by logistic regression. The trial was terminated at 78% of planned enrollment after meeting stopping criteria for futility. In total, 940 patients were randomized, and 921 patients were included in the intention-to-treat analysis. Intubation or death occurred in 199/614 (32.4%) patients in the convalescent plasma arm and 86/307 (28.0%) patients in the standard of care arm-relative risk (RR) = 1.16 (95% confidence interval (CI) 0.94-1.43, P = 0.18). Patients in the convalescent plasma arm had more serious adverse events (33.4% versus 26.4%; RR = 1.27, 95% CI 1.02-1.57, P = 0.034). The antibody content significantly modulated the therapeutic effect of convalescent plasma. In multivariate analysis, each standardized log increase in neutralization or antibody-dependent cellular cytotoxicity independently reduced the potential harmful effect of plasma (odds ratio (OR) = 0.74, 95% CI 0.57-0.95 and OR = 0.66, 95% CI 0.50-0.87, respectively), whereas IgG against the full transmembrane spike protein increased it (OR = 1.53, 95% CI 1.14-2.05). Convalescent plasma did not reduce the risk of intubation or death at 30 d in hospitalized patients with COVID-19. Transfusion of convalescent plasma with unfavorable antibody profiles could be associated with worse clinical outcomes compared to standard care., (© 2021. The Author(s).)
- Published
- 2021
- Full Text
- View/download PDF
146. Lessons learned in the collection of convalescent plasma during the COVID-19 pandemic.
- Author
-
Wendel S, Land K, Devine DV, Daly J, Bazin R, Tiberghien P, Lee CK, Arora S, Patidar GK, Khillan K, Smid WM, Vrielink H, Oreh A, Al-Riyami AZ, Hindawi S, Vermeulen M, Louw V, Burnouf T, Bloch EM, Goel R, Townsend M, and So-Osman C
- Subjects
- COVID-19 Testing, Humans, Immunization, Passive, SARS-CoV-2, COVID-19 Serotherapy, COVID-19 therapy, Pandemics prevention & control
- Abstract
Background: The lack of definitive treatment or preventative options for COVID-19 led many clinicians early on to consider convalescent plasma (CCP) as potentially therapeutic. Regulators, blood centres and hospitals worldwide worked quickly to get CCP to the bedside. Although response was admirable, several areas have been identified to help improve future pandemic management., Materials and Methods: A multidisciplinary, multinational subgroup from the ISBT Working Group on COVID-19 was tasked with drafting a manuscript that describes the lessons learned pertaining to procurement and administration of CCP, derived from a comprehensive questionnaire within the subgroup., Results: While each country's responses and preparedness for the pandemic varied, there were shared challenges, spanning supply chain disruptions, staffing, impact of social distancing on the collection of regular blood and CCP products, and the availability of screening and confirmatory SARS-CoV-2 testing for donors and patients. The lack of a general framework to organize data gathering across clinical trials and the desire to provide a potentially life-saving therapeutic through compassionate use hampered the collection of much-needed safety and outcome data worldwide. Communication across all stakeholders was identified as being central to reducing confusion., Conclusion: The need for flexibility and adaptability remains paramount when dealing with a pandemic. As the world approaches the first anniversary of the COVID-19 pandemic with rising rates worldwide and over 115 million cases and 2·55 million deaths, respectively, it is important to reflect on how to better prepare for future pandemics as we continue to combat the current one., (© 2021 International Society of Blood Transfusion.)
- Published
- 2021
- Full Text
- View/download PDF
147. SARS-CoV-2 seroprevalence among blood donors in Québec, and analysis of symptoms associated with seropositivity: a nested case-control study.
- Author
-
Lewin A, Therrien R, De Serres G, Grégoire Y, Perreault J, Drouin M, Fournier MJ, Tremblay T, Beaudoin J, Beaudoin-Bussières G, Prévost J, Gendron-Lepage G, Finzi A, Bernier F, Bazin R, Germain M, and Delage G
- Subjects
- Adolescent, Adult, Aged, Case-Control Studies, Cross-Sectional Studies, Female, Humans, Male, Middle Aged, Quebec epidemiology, Seroepidemiologic Studies, Symptom Assessment, Young Adult, Antibodies, Viral blood, Blood Donors statistics & numerical data, COVID-19 epidemiology, Pandemics, SARS-CoV-2 immunology
- Abstract
Objectives: A substantial proportion of individuals infected with SARS-CoV-2 do not experience noticeable symptoms typical of COVID-19. Our objectives were to evaluate the impact of the first wave of the pandemic in Québec by measuring SARS-CoV-2 antibody seroprevalence in a convenience sample of healthy blood donors and to study the association between seropositivity and the occurrence of COVID-19 symptoms., Methods: The study design was a cross-sectional serological survey with a nested case-control study. Residual blood samples from donations collected between May 25 and July 9, 2020 (well before vaccination rollout) in the province of Québec were tested for anti-Spike RBD antibodies by ELISA. Seropositive donors and a control group of seronegative donors were questioned about prior COVID-19 symptoms. All qualified blood donors were eligible for participation., Results: A total of 7691 blood donors were included in the study. After adjustments, the seroprevalence rate was 2.2% (95% CI 1.9-2.6). Seropositive donors reported one or more symptoms in a proportion of 52.2% (95% CI 44.2-60.1); this proportion was 19.1% (95% CI 13.4-26.1) among seronegative donors, suggesting that approximately 50-66% of all infections were asymptomatic. Univariate analysis of associations between symptoms and seropositivity revealed that except for rhinorrhea, all symptoms were significantly associated with seropositivity., Conclusion: Assuming that blood donors are fairly representative of the general adult population, this study shows that less than 3% of 18-69-year-olds have been infected during the first wave of the pandemic in the province of Québec. Our data also confirm that many infections escaped detection, including a substantial proportion that were asymptomatic.
- Published
- 2021
- Full Text
- View/download PDF
148. Longitudinal analysis of humoral immunity against SARS-CoV-2 Spike in convalescent individuals up to 8 months post-symptom onset.
- Author
-
Anand SP, Prévost J, Nayrac M, Beaudoin-Bussières G, Benlarbi M, Gasser R, Brassard N, Laumaea A, Gong SY, Bourassa C, Brunet-Ratnasingham E, Medjahed H, Gendron-Lepage G, Goyette G, Gokool L, Morrisseau C, Bégin P, Martel-Laferrière V, Tremblay C, Richard J, Bazin R, Duerr R, Kaufmann DE, and Finzi A
- Abstract
With the recent approval of highly effective coronavirus disease 2019 (COVID-19) vaccines, functional and lasting immunity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is currently under investigation as antibody levels in plasma were shown to decline during convalescence. Since the absence of antibodies does not equate to absence of immune memory, we evaluate the presence of SARS-CoV-2-specific memory B cells in convalescent individuals. Here, we report a longitudinal assessment of humoral immune responses on 32 donors up to 8 months post-symptom onset. Our observations indicate that anti-Spike and anti-receptor binding domain (RBD) immunoglobulin M (IgM) in plasma decay rapidly, whereas the reduction of IgG is less prominent. Neutralizing activity also declines rapidly when compared to Fc-effector functions. Concomitantly, the frequencies of RBD-specific IgM+ B cells wane significantly when compared to RBD-specific IgG+ B cells, which remain stable. Our results add to the current understanding of immune memory following SARS-CoV-2 infection, which is critical for secondary infection prevention and vaccine efficacy., Competing Interests: The authors declare no competing interests., (© 2021 The Authors.)
- Published
- 2021
- Full Text
- View/download PDF
149. Convalescent plasma for adults with acute COVID-19 respiratory illness (CONCOR-1): study protocol for an international, multicentre, randomized, open-label trial.
- Author
-
Bégin P, Callum J, Heddle NM, Cook R, Zeller MP, Tinmouth A, Fergusson DA, Cushing MM, Glesby MJ, Chassé M, Devine DV, Robitalle N, Bazin R, Shehata N, Finzi A, McGeer A, Scales DC, Schwartz L, Turgeon AF, Zarychanski R, Daneman N, Carl R, Amorim L, Gabe C, Ellis M, Sachais BS, Loftsgard KC, Jamula E, Carruthers J, Duncan J, Lucier K, Li N, Liu Y, Armali C, Kron A, Modi D, Auclair MC, Cerro S, Avram M, and Arnold DM
- Subjects
- Adult, Bisoprolol, Humans, Immunization, Passive, Multicenter Studies as Topic, Randomized Controlled Trials as Topic, SARS-CoV-2, Treatment Outcome, COVID-19 Serotherapy, COVID-19 therapy, Coronavirus Infections
- Abstract
Background: Convalescent plasma has been used for numerous viral diseases including influenza, severe acute respiratory syndrome, Middle East respiratory syndrome and Ebola virus; however, evidence to support its use is weak. SARS-CoV-2 is a novel coronavirus responsible for the 2019 global pandemic of COVID-19 community acquired pneumonia. We have undertaken a randomized controlled trial to assess the efficacy and safety of COVID-19 convalescent plasma (CCP) in patients with SARS-CoV-2 infection., Methods: CONCOR-1 is an open-label, multicentre, randomized trial. Inclusion criteria include the following: patients > 16 years, admitted to hospital with COVID-19 infection, receiving supplemental oxygen for respiratory complications of COVID-19, and availability of blood group compatible CCP. Exclusion criteria are : onset of respiratory symptoms more than 12 days prior to randomization, intubated or imminent plan for intubation, and previous severe reactions to plasma. Consenting patients are randomized 2:1 to receive either approximately 500 mL of CCP or standard of care. CCP is collected from donors who have recovered from COVID-19 and who have detectable anti-SARS-CoV-2 antibodies quantified serologically. The primary outcome is intubation or death at day 30. Secondary outcomes include ventilator-free days, length of stay in intensive care or hospital, transfusion reactions, serious adverse events, and reduction in SARS-CoV-2 viral load. Exploratory analyses include patients who received CCP containing high titre antibodies. A sample size of 1200 patients gives 80% power to detect a 25% relative risk reduction assuming a 30% baseline risk of intubation or death at 30 days (two-sided test; α = 0.05). An interim analysis and sample size re-estimation will be done by an unblinded independent biostatistician after primary outcome data are available for 50% of the target recruitment (n = 600)., Discussion: This trial will determine whether CCP will reduce intubation or death non-intubated adults with COVID-19. The trial will also provide information on the role of and thresholds for SARS-CoV-2 antibody titres and neutralization assays for donor qualification., Trial Registration: Clinicaltrials.gov NCT04348656 . Registered on 16 April 2020.
- Published
- 2021
- Full Text
- View/download PDF
150. High-throughput detection of antibodies targeting the SARS-CoV-2 Spike in longitudinal convalescent plasma samples.
- Author
-
Anand SP, Prévost J, Richard J, Perreault J, Tremblay T, Drouin M, Fournier MJ, Lewin A, Bazin R, and Finzi A
- Subjects
- COVID-19 therapy, Female, HEK293 Cells, Humans, Immunization, Passive, Longitudinal Studies, Male, COVID-19 Serotherapy, Antibodies, Viral blood, COVID-19 blood, SARS-CoV-2 metabolism, Spike Glycoprotein, Coronavirus blood
- Abstract
Background: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus is the cause of the ongoing coronavirus disease 2019 (COVID-19) pandemic, infecting millions of people and causing more than two million deaths. The SARS-CoV-2 Spike glycoproteins mediate viral entry and represent the main target for antibody responses. Humoral responses were shown to be important for preventing and controlling infection by coronaviruses. A promising approach to reduce the severity of COVID-19 is the transfusion of convalescent plasma. However, longitudinal studies revealed that the level of antibodies targeting the receptor-binding domain (RBD) of the SARS-CoV-2 Spike declines rapidly after the resolution of the infection., Study Design and Methods: To extend this observation beyond the RBD domain, we performed a longitudinal analysis of the persistence of antibodies targeting the full-length SARS-CoV-2 Spike in the plasma from 15 convalescent donors. We generated a 293T cell line constitutively expressing the SARS-CoV-2 Spike and used it to develop a high-throughput flow cytometry-based assay to detect SARS-CoV-2 Spike-specific antibodies in the plasma of convalescent donors., Results and Conclusion: We found that the level of antibodies targeting the full-length SARS-CoV-2 Spike declines gradually after the resolution of the infection. This decline was not related to the number of donations but strongly correlated with the decline of RBD-specific antibodies and the number of days post-symptom onset. These findings help to better understand the decline of humoral responses against the SARS-CoV-2 Spike and provide important information on when to collect plasma after recovery from active infection for convalescent plasma transfusion., (© 2021 AABB.)
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.